Webdal-gene Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population with a Recent ACS This study is in follow-up. Primary Objective: A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. WebJul 27, 2024 · DalCor would like to thank all the patients, investigators, and study sites for their continued participation in the dal-GenE study. About DalCor DalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision …
The dal-GenE trial: A case study of precision medicine in …
WebApr 1, 2024 · Study design dal-GenE is a double-blind, parallel group, placebo-controlled randomized trial in patients recently hospitalized for ACS and confirmed to have the AA … WebApr 4, 2024 · In this study, we evaluated the gene expression of the pulmonary SP (SP-A1, SP-A2, SP-B, SP-C and SP-D) in human NCI-H441 cells following an A. fumigatus infection. We tested the effect of DAL, DHN-melanin-deficient, GAG-deficient and GM-deficient mutant A. fumigatus strains as well as culture filtrates incubated with cells for 4 and 8 h. literacy rate for greece
dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes …
WebMar 7, 2024 · About the dal-GenE Study The double-blind, randomized, placebo-controlled, multicenter Phase 3 clinical trial will enroll 5,000 patients recently hospitalized with ACS … WebJul 21, 2024 · dal-GenE was a double-blind, parallel-group, placebo-controlled, randomized trial comparing orally administered dalcetrapib 600 mg once daily with placebo in a 1:1 … WebApr 26, 2016 · LONDON and MONTREAL, April 26, 2016 – DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. importance of application security